Selank - Generic Peptides

Buy Selank by Generic Peptides at XSteroids. Selank is a synthetic heptapeptide built as an analogue of tuftsin, the natural immunomodulatory tetrapeptide, and it was developed at the Institute of Molecular Genetics in Moscow. Generic Peptides lists it as lyophilized powder in two fills, a 5 mg vial and a 30 mg vial. The evidence base is unusual: solid animal pharmacology, a registered medicine status inside Russia, and almost no Western clinical work. This page separates those layers, then covers what is in the vial, the mechanisms studied, the mixing arithmetic, research amounts, stacking, storage and legal status.

What Selank Is and What You Are Buying

What you receive is a single glass vial of white lyophilized powder, filled at 5 mg or 30 mg, with a stopper held under a crimp cap. Mixing items are the buyer's responsibility, since the diluent and the consumables are excluded from this order. Both fills sit on one page, so strength shows up only on the pack option and never in the product title.

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP, a seven-amino-acid extension of the tuftsin fragment. Its mass is near 752 g/mol, its CAS number is 129954-34-3 and its PubChem record is 11765600. No human half-life has been established. One distinction belongs here at the start: the registered product in Russia is a nasal solution, while this vial is a research powder. They share a molecule but not a formulation, and nothing here should be read as a description of the pharmacy product.

How Selank Works in Research

Tuftsin, interleukins and the immune side

Selank began as a stabilised analogue of tuftsin, a tetrapeptide fragment of immunoglobulin that influences immune cell behaviour. The pharmacological work follows that origin: the peptide modulates expression of interleukin-6 and shifts the balance of T-helper cytokines in animal models. That cytokine side is the reason the compound is described both as an anxiolytic and as an immunomodulator in Russian literature.

Monoamines, BDNF and enkephalin breakdown

In Wistar rats the peptide changes the concentration of monoamine neurotransmitters and the metabolism of serotonin. It also raises brain-derived neurotrophic factor, or BDNF, in the hippocampus quickly after administration. A third and more specific mechanism has been measured directly: Selank and Semax both inhibit the enzymes that degrade enkephalins and other regulatory peptides, with an IC50 near 10 micromolar in the published work. That enzyme inhibition is a plausible explanation for a short-term effect that a peptide with a short lifetime could not otherwise produce.

The anxiolytic reading

Animal models of depression and anhedonia respond to the peptide with antidepressant-like behaviour. The human side of the story is Russian and clinical rather than experimental: comparative work against benzodiazepines and barbiturates reported an anxiolytic effect without sedation and without the memory impairment usually associated with those drugs, at least at the lower doses studied. Those are small studies from a specific research tradition, and no independent Western replication exists.

What to Expect from Selank Research

The honest split is this: the marker-level evidence comes from animals, and the clinical evidence comes from small Russian human studies. In animals the measured changes include cytokine expression, monoamine levels and hippocampal BDNF. In people the reported outcomes are anxiety rating scales and tolerability rather than biochemical endpoints, and the clinical scheme most often cited runs for about 14 days of intranasal use.

What does not exist is a large randomised trial outside Russia, a pharmacokinetic profile in humans, or a modern re-analysis of the older clinical data. A buyer should therefore expect a compound with a plausible mechanism, a real registered use in one country, and an evidence base that would not satisfy a Western regulator today. Nothing here claims a treatment effect for any condition.

Dosing Selank for Research

Mixing a 5 mg or 30 mg vial

The millilitres you add set everything else. Add 2 ml to the 5 mg vial and each ml holds 2.5 mg, so the 10-unit line on a U-100 syringe reads 250 mcg; use 5 ml instead and the vial sits at 1 mg/ml with 100 mcg under the same line. The 30 mg vial follows the same rule at a larger scale: 10 ml puts it at 3 mg/ml, which is 300 mcg per 10 units, and 30 ml at 1 mg/ml with 100 mcg per 10 units. Roll the vial between the palms; do not shake it, and write the volume on the label.

Intranasal and subcutaneous research

The Russian clinical scheme uses a diluted nasal solution three times a day for about two weeks. Vendor research notes describe roughly 250 to 500 mcg per intranasal dose, with the same range quoted for subcutaneous use. Nothing resembling a dose-finding study produced those numbers; they are conventions, and with a nasal preparation the outcome depends as much on technique and dilution as on the amount.

Stacking Selank With Other Cognitive Peptides

The usual partner is Semax, the other Russian peptide drug and the closest relative, which shares the enkephalin-degradation mechanism. Sleep-focused plans often add DSIP, and MET5 is the enkephalin peptide used in mood research. In a longevity frame Selank sits beside Epitalon, NAD+, Glutathione and Thymalin, the thymus peptide used for immune-side research. No controlled work has tested any of those combinations.

Recovery and Breaks Around Selank

Selank sits outside the hormonal axis, so it neither suppresses testosterone nor calls for a post-cycle recovery protocol. The clinical scheme itself defines the cycle: about 14 days of use, with a break before repeating. If the plan also includes an immune-oriented peptide such as Thymalin or Thymosin Alpha-1, schedule those separately rather than stacking several immune-active compounds at once.

Selank Safety and Legal Status

Approved in Russia, nowhere else

Selank is registered in Russia for generalised anxiety disorder and neurasthenia, and it is also used there as an immunomodulator. It is not approved by the FDA or the EMA and is effectively unavailable as a pharmacy product outside Russia and Ukraine. The vial sold here is not that registered nasal product; it is a research powder that has not been through the regulatory process.

What the safety record does and does not cover

Published Russian studies are too small to reveal a rare side effect, and there is no safety register for Selank anywhere outside Russia. Irritation, redness or tenderness at the application site is the expected local reaction. Anyone taking psychotropic medication, anyone with a diagnosed anxiety disorder, and anyone who is pregnant or breastfeeding should seek medical care rather than use a research peptide, and the product is not intended for people under 18.

Anti-doping status

Search the WADA Prohibited List and Selank does not appear, and no separate guidance addresses it. Absence from the list is a gap in the data, not a statement of permission, and the vial is still supplied for laboratory research alone.

Keeping Selank: Storage and Vial Handling

Until water is added, the powder is most stable in a refrigerator held at 2 to 8 C, shielded from light, with a freezer reserved for long gaps between experiments. A reconstituted solution should stay in the same cold range and be used up within 28 to 30 days; freezing it is not advised. Warm the vial to room temperature first, disinfect the stopper with alcohol, and record the volume used so the concentration in the syringe matches your notes.

Why Buy Selank from XSteroids?

At XSteroids both Selank fills, 5 mg and 30 mg, are held in the Generic Peptides category next to the rest of the cognitive and sleep range. The Semax card describes the other Russian peptide drug and the DSIP card covers sleep-architecture research. Match the fill to the arithmetic above and finish any mixed solution inside the 30-day window.